Cancers, Free Full-Text
Por um escritor misterioso
Descrição
Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 biology and selinexor sensitivity in childhood cancer is only recently being explored. In this review, we will focus on the differential biology of childhood and adult cancers as it relates to XPO1 and key cargo proteins. We will further explore the current state of pre-clinical and clinical development of XPO1 inhibitors in childhood cancers. Finally, we will outline potentially promising future therapeutic strategies for, as well as potential challenges to, integrating XPO1 inhibition to improve outcomes for children with cancer.
Event-free Survival with Pembrolizumab in Early Triple-Negative
Cancer treatment and survivorship statistics, 2022 - Miller - 2022
Skin Cancer Types, Symptoms and Information
Loco Evolution Binary Patch - Colaboratory
PDF) Combination of tumor markers predicts progression and
PDF) Predictors of recurrence free survival for patients with
Cancers, Free Full-Text
Know the signs of cancer to catch it early
Hallmarks of Cancer: The Next Generation: Cell
Remission, cancer-free, no evidence of disease: What's the
Cancers, Free Full-Text
Pembrolizumab as Second-Line Therapy for Advanced Urothelial
A Randomized Trial of Letrozole in Postmenopausal Women after Five
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
de
por adulto (o preço varia de acordo com o tamanho do grupo)
